Immunoassay - Market Insights, Competitive Landscape, and Market Forecast - 2030

Immunoassay Market By Product (Reagents & Kits And Instruments), Technology (Radioimmunoassay, Enzyme-Linked Immunoassay, Chemiluminescence Immunoassay, Fluoroimmunoassay, And Others), Sample (Blood, Urine, Saliva, And Others), Application (Oncology, Cardiology, Infectious Disease Testing, Endocrinology, Autoimmune Disorders, And Others), End-User (Hospitals & Clinics, Diagnostic Labs, Pharmaceuticals & Biotech Industries, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of chronic diseases such as cancer, lifestyle diseases such as diabetes mellitus, and others, and the growing prevalence of infectious diseases such as hepatitis, hiv, and others

The global Immunoassay market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 7.53% during the forecast period from 2024 to 2030. The demand for immunoassay is primarily being boosted by the increasing prevalence of chronic disorders such as cancers, and lifestyle disorders such as diabetes mellitus, among others. The increase in various oncological disorders such as breast cancer and prostate cancer is a key factor influencing the positive growth of the market. Further, the rising awareness among people regarding early disease diagnosis is also contributing to the overall growth of the immunoassay market during the forecast period from 2024-2030.

Immunoassay Market Dynamics:

As per the International Diabetes Federation (IDF) 2021, worldwide around 537 million adults aged between 20 and 79 years had diabetes in the year 2021. Also, according to the same source around 643 million people will be suffering from diabetes by 2030, globally. The various biomarkers associated with diabetes mellitus such as insulin and C-peptide can be detected accurately with immunoassay. Thus, the rising prevalence of diabetes will increase the demand for immunoassay, thereby contributing to its market growth.

As per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, and 1.93 million cases of colon and rectal cancer, reported in the year 2020 globally. Therefore, the rising cases of cancers such as lung, breast, and prostate cancer amongst the adult population as well as the recommendation of annual tests for biomarkers of these diseases by doctors is going to accelerate the market for immunoassay.

Further, the rising cases of infectious disorders such as HIV, hepatitis, and others is another key driver for the immunoassay market, as immunoassays are widely used for the diagnosis of infectious disorders. According to the World Health Organization (WHO) 2022, it was estimated that in 2022, around 354 million people were living with Hepatitis B or C infections, globally. Therefore, the increasing cases of infectious diseases will further increase the demand for diagnosis, thus contributing to market growth.

However, technical issues associated with the immunoassay test kits and instruments, high costs, along with the lack of skilled professionals required to perform these complicated tests are some of the market barriers that may restrict the growth of the immunoassay market.

Immunoassay Market Segment Analysis:

Immunoassay Market by Product (Reagents & Kits and Instruments), Technology (Radioimmunoassay, Enzyme-Linked Immunoassay, Chemiluminescence Immunoassay, Fluoroimmunoassay, and Others), Sample (Blood, Urine, Saliva, and Others), Application (Oncology, Cardiology, Infectious Disease Testing, Endocrinology, Autoimmune Disorders, and Others), End-User (Hospitals & Clinics, Diagnostic Labs, Pharmaceuticals & Biotech Industries, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the Immunoassay market, the reagents & kits category is expected to amass a significant revenue share in the year 2023. This can be attributed to the high demand and consumption of immunoassay kits and reagents and the increasing number of immunoassay tests performed, due to the increasing number of chronic and infectious disorders around the globe. Additionally, various advantages provided by immunoassay kits such as high sensitivity and strong specificity are also some of the factors contributing to the growth of the segment.

Further, the kits and reagents are required for every test making them an integral part of the testing process.

Furthermore, with the growing demand for this segment, numerous new products are being launched in the market. In February 2021, Agilent Technologies launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit, which is used for the detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.

Therefore, owing to the above-mentioned factors, the reagents & kits category is expected to register significant growth, thereby driving the growth of the overall Immunoassay market during the forecast period.

North America is expected to dominate the overall Immunoassay Market:

Among all the regions, North America is estimated to account for the largest share of the Immunoassay market in the year 2023. This can be attributed to the presence of unhealthy lifestyles in the region contributing to a large patient pool suffering from various lifestyle disorders such as diabetes mellitus and thyroid diseases. Additionally, high consumer awareness regarding disease diagnosis, government support, and a dominant market in terms of product development and launches are among other factors influencing the growth of the market in the region.

One of the prominent factors supporting the growth of the North America immunoassay market is the extensive use of immunoassay in the detection of tumor markers indicating cancer development. For instance, according to National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Additionally, as per the same source prostate, lung, and colorectal cancer accounted for 43% of the cancer cases in men, and breast, lung, and colorectal making up to 50% of cancer cases in women.

Further, according to the data provided by The Government of Canada 2021, cancer is one of the leading causes of death in Canada. In 2021, around 229,200 Canadians were diagnosed with cancer and 84,600 people died from cancer in Canada. This indicates the huge need for early detection of the diseases, therefore leading to the growth of immunoassay market in the region.

Moreover, the rise in chronic and cardiovascular diseases such as coronary artery diseases, and stroke among the US population is another driver of the immunoassay market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, around 18.2 million people aged 20 or above had coronary artery disease in the United States. Also, as per the same source around 805,000 people face heart attacks every year in the United States. This indicates the huge need for immunoassay for the detection of cardiac markers assisting in the identification of cardiovascular disorders and therefore leading to market growth of immunoassay.

Therefore, the factors mentioned above, and the increasing awareness of people regarding early disease diagnosis in the region are some of the important factors which are thereby responsible for driving the market in North America during the forecast period.

Immunoassay Market Key Players:

Some of the key market players operating in the immunoassay market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, ALPCO, Autobio, PHC Corporation, Trivitorn Healthcare, Werfen, Danaher Corporation, Sysmex Corporation, Awareness Technology Inc, ZECEN Biotech Co., Quidel Corporation, among others.

Recent Developmental Activities in the Immunoassay Market:

• In August 2023, Fapon Biotech launched its latest chemiluminescence immunoassay analyzer. The Shine i8000/9000 consists of innovative features and has an ultra-high throughput of 900 tests per hour.
• In November 2022, Gethin Biotech introduced the new MAGICAL 6000 chemiluminescence immunoassay Analyzer at MEDICA.
• In April 2021, Snibe, Diagnostic received CE marking for Maglumi HIV Ab/Ag Combi CLIA kit which detects HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen.

Key Takeaways from the Immunoassay Market Report Study

• Market size analysis for current immunoassay market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/and technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global immunoassay market.
• Various opportunities available for the other competitors in the immunoassay market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current immunoassay market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for immunoassay market growth in the coming future?

Target Audience who can be benefited from this Immunoassay Market Report Study

• Immunoassay product providers
• Research organizations and consulting companies
• Immunoassay-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Immunoassay
• Various end-users who want to know more about the immunoassay market and the latest technological developments in the Immunoassay market

Frequently Asked Questions for the Immunoassay Market:

1. What is meant by Immunoassay?

Immunoassays are bioanalytical methods that usually employ the specificity of antigen-antibody reactions to detect the target molecules in the samples. These are highly specific and sensitive and the reagents used are antibodies and purified antigens, which contribute to their great specificity.

2. What is the market for global Immunoassay?

The global Immunoassay market is poised for significant growth, projected to achieve a remarkable Compound Annual Growth Rate (CAGR) of 7.53% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Immunoassay market?

The immunoassay market is slated to witness prosperity owing to factors such as the growing prevalence of chronic diseases such as cancers, thyroid diseases, lifestyle disorders such as diabetes mellitus, and others. Additionally, there is a large patient pool suffering from various cardiovascular and autoimmune disorders globally. Further, the rising awareness of health, the growing focus on improving accuracy, affordability, portability, and usability of immunoassay for end-users are expected to result in the appreciable revenue growth of the immunoassay market during the forecast period (2024-2030).

4. Who are the key players operating in the global immunoassay market?

Some of the key market players operating in the Immunoassay market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, ALPCO, Autobio, PHC Corporation, Trivitorn Healthcare, Werfen, Danaher Corporation, Sysmex Corporation, Awareness Technology Inc., ZECEN Biotech Co., Quidel Corporation, among others.

5. Which region has the highest share in the global immunoassay market?

North America is expected to dominate the overall Immunoassay Market during the forecast period from 2024 to 2030. Due to the presence of a large patient pool associated with various diseases such as diabetes mellitus, and cardiovascular diseases this can be further attributed to the poor lifestyle of people. Further, the region has a very potent market for product development and launches, a high level of consumer knowledge regarding new market launches, support from the government, and the presence of local and significant market players.